ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1514

Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment

Erik Cimé-Aké1, Guadalupe Lima2, Emilio G. Lazarini1, Sandra Juárez3, Luis Llorente2 and Hilda Fragoso-Loyo1, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Neurology and Psychiatry Department, Mexico City, Mexico

Meeting: ACR Convergence 2024

Keywords: Cognitive dysfunction, Systemic lupus erythematosus (SLE), T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Cognitive impairment (CI) in systemic lupus erythematosus (SLE) may result from a chronic pro-inflammatory state in which immunosenescent and exhausted T-lymphocytes could be involved. This study investigates the expression of senescent and exhausted T cells markers in SLE patients with CI.

Methods: We included women aged 18-50 years, classified with SLE according to the EULAR/ACR 2019 criteria. We excluded women with other autoimmune diseases except antiphospholipid syndrome or Sjögren’s syndrome, administration of any biologic drug < 6 months prior to study entry, clinical SLEDAI-2K >0, SDI ≥1, current prednisone >7.5 mg/day, education level ≤6 years, pregnancy or premature ovarian failure, active infection, malignant disease, history of other neuropsychiatric manifestations, other chronic comorbidities or major depressive disorder. Healthy women (HC) paired for age ±5 years were also included. All patients underwent a neurocognitive battery applied by an expert neuropsychologist, assessing eight cognitive domains: concentration, verbal memory, visuospatial memory, language, processing speed, motor speed, problem solving and executive function. CI was defined when a subject had scores ≥2 standard deviation below the mean of the normative data in ≥1 cognitive domain. After the neurocognitive assessment patients were classified as: SLE with CI, SLE without CI and HC. Relative expression of senescence markers (CD27, CD28, CD57, KLRG1) and inhibitory markers (PD-1, PD-L1, Tim-3, CTLA-4 and LAG-3) in CD4+ and CD8+ lymphocytes were determined by flow cytometry, dimensionality reduction and clustering analysis. We generated tSNE maps using concatenated files with an equal number of CD3+ cells from eight representative trios of patients from each study group. Demographic and clinical data were recorded.

Results: Thirteen patients with SLE with CI, fourteen SLE without CI and ten HC were analyzed. The median age of patients studied was similar. SLE patients with CI had lower educational level than the SLE without CI and HC, and longer disease duration compared to SLE patients without CI. Disease activity and damage accrual was similar between the SLE groups (Table 1). In SLE patients with CI, the most frequently impaired cognitive domain was motor speed (76.9%), followed by visuospatial memory (30.8%), verbal memory (7.7%), language (7.7%), processing speed (7.7%) and problem solving (7.7%). SLE patients with CI had lower levels of CD4+ Naive, CD4+CD45RA+, CD4+CTLA-4+ and CD8+PD-L1+, but higher levels of CD8+ (Table 1, Figure 1). We could identify three representative CD8+ and four CD4+ subpopulations according to their relative expression of surface markers (Figure 2).

Conclusion: Significant differences were identified among the three groups in relation to markers of cellular exhaustion but not of immunosenescence. In SLE with CI, PD-L1, Tim-3, CTLA-4 and LAG-3 in CD4+ and Tim-3 and PD-L1 in CD8+ expression was lower compared to SLE without CI and HC. The study suggests the possibility that cellular exhaustion play a role in CI in SLE and could be useful for its diagnosis.

Supporting image 1

Table 1. Demographic, clinical, subpopulations and expression of senescent and exhausted T cells markers in CD4+ and CD8+ of studied patients.
Data are expressed as proportions (percentages) or medians (interquartile ranges). Statistical analysis: Chi-square or Fisher’s exact tests were used for nominal variables, the Wilcoxon rank-sum test was used for numerical variables.
CM: central memory, EM: effector memory, TEMRA: effector memory T cells re-expressing CD45RA.
*Statistically significant.

Supporting image 2

Figure 1. Statistical significant differences in subpopulations and senescent and exhaustion markers in T cells of studied patients.
HC: healthy control, SLE: systemic lupus erythematosus, CI: cognitive impairment.

Supporting image 3

Figure 2. Surface marker distribution in CD4+ and CD8+ T cells is depicted in the tSNE map.
HC: healthy control, SLE: systemic lupus erythematosus, CI: cognitive impairment.


Disclosures: E. Cimé-Aké: None; G. Lima: None; E. G. Lazarini: None; S. Juárez: None; L. Llorente: None; H. Fragoso-Loyo: None.

To cite this abstract in AMA style:

Cimé-Aké E, Lima G, G. Lazarini E, Juárez S, Llorente L, Fragoso-Loyo H. Immunosenescent and Exhausted T Cells in Patients with Systemic Lupus Erythematosus and Cognitive Impairment [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/immunosenescent-and-exhausted-t-cells-in-patients-with-systemic-lupus-erythematosus-and-cognitive-impairment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunosenescent-and-exhausted-t-cells-in-patients-with-systemic-lupus-erythematosus-and-cognitive-impairment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology